High lipoprotein(a) levels are linked to a sharply higher risk of major cardiovascular events, including stroke and cardiovascular death. That is the headline of a new analysis of 20,070 adults from three U.S. National Institutes of Health (NIH) trials.

The high Lp(a) cardiovascular risk data appeared at two cardiology meetings in Montreal. The first was the Society for Cardiovascular Angiography & Interventions (SCAI) 2026 Scientific Sessions. The second was the Canadian Association of Interventional Cardiology/Association Canadienne de cardiologie d'intervention (CAIC-ACCI) Summit.

What the analysis measured

Researchers analysed blood from 20,070 adults aged 40 and older. They came from three large NIH trials: ACCORD, PEACE, and SPRINT. The average age was about 65 years. About 65% were male.

Participants were grouped by Lp(a) level. Bands ran from low (under 75 nmol/L) to very high (175 nmol/L or above). The team was also split by existing heart disease status.

Median follow-up ran nearly 4 years. Researchers tracked major adverse cardiovascular events (MACE) — heart attack, stroke, and cardiovascular death. About 7.3% of participants had a MACE.

The high Lp(a) cardiovascular risk pattern was clearest at the top end. Adults with Lp(a) at or above 175 nmol/L showed sharply elevated rates of cardiovascular death and stroke. The signal was strongest in those who already had cardiovascular disease.

The link was not uniform across all outcomes. Higher Lp(a) levels did not raise the risk of heart attack in this analysis.

Why the threshold matters

Cheng-Han Chen, MD, said the cutoff sits well above usual clinical alarm levels. Chen, an interventional cardiologist not involved in the study, is the medical director of the Structural Heart Program at MemorialCare Saddleback Medical Centre, Laguna Hills, CA.

Chen told Medical News Today: "We would generally consider a Lp(a) level of over 125 nmol/L to be high. The threshold of ≥175 nmol/L identified in the study would be considered extremely high and should drive aggressive management of other cardiovascular risk factors."

The new high Lp(a) cardiovascular risk findings give clinicians a sharper line for spotting patients with high residual risk. Many are already on statins, yet recurrent vascular events still occur after LDL is brought down.

What is Lp(a) and why does it matter

Lipoprotein(a) is a cholesterol-carrying particle in the blood. It is structurally similar to low-density lipoprotein (LDL), often called "bad" cholesterol. Standard prevention uses lipid-lowering therapies to lower LDL.

Lp(a) carries something extra. It contains proteins linked to blood clotting. That profile may make Lp(a) a worse marker of cardiovascular disease than LDL alone.

About 1 in 5 people carry elevated Lp(a) — around 20% of the global population. Despite that, Lp(a) is rarely tested in routine care. Inconsistent measurement and a thin therapy pipeline have held screening back.

The high Lp(a)- associated cardiovascular risk results add weight to the case for broader testing. They point to a clear 175 nmol/L threshold for stratifying patients and tailoring prevention.

Genetics and the case for testing

Lp(a) levels are mostly genetic. Roughly 70-90% of an adult's Lp(a) is determined by the LPA gene. Diet, exercise, and lifestyle changes barely move the number.

That makes a one-time test useful. Lp(a) testing is simple and inexpensive. The result can guide care for life.

"We recommend that all adults should have their Lp(a) level tested at least once, in order to help assess their cardiovascular risk," Chen told MNT.

For high-band patients, clinicians may push LDL lower, tighten blood pressure and diabetes control, and watch the heart more closely. Chen called for aggressive LDL management, along with lifestyle changes. Those include regular exercise and a heart-healthy diet low in sodium and saturated fat. He also urged no tobacco or alcohol.

Newer therapies that target Lp(a) directly are in development. Those drugs could open the door to more personalised prevention.

The researchers said further work is needed to clarify how Lp(a) affects subgroups such as people with chronic kidney disease or peripheral artery disease.

The growing body of evidence linking high Lp(a) to cardiovascular risk is pushing toward routine Lp(a) measurement. Coverage on Medigear.uk shows why hospital teams must follow how the high Lp(a) cardiovascular risk threshold reshapes prevention.

Source: Originating coverage based on Medical News Today reporting on findings presented at the Society for Cardiovascular Angiography & Interventions (SCAI) 2026 Scientific Sessions and the CAIC-ACCI Summit in Montreal — analysis of 20,070 adults from the NIH ACCORD, PEACE, and SPRINT trials, with expert commentary from Cheng-Han Chen, MD, MemorialCare Saddleback Medical Centre.